CRISPR Therapeutics AG (CRSP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 350M 700M 1.1B FY15: 247K FY16: 5.2M FY17: 41M FY18: 3.1M FY19: 289.6M FY20: 719K FY21: 915M FY22: 1.2M FY23: 371.2M FY24: 37.3M FY25: 3.5M FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-750M -500M -250M 0 250M 500M 750M FY14: -6.6M FY15: -25.7M FY16: -68.1M FY17: -64.6M FY18: -158.9M FY19: 46.7M FY20: -354.4M FY21: 373.5M FY22: -673.2M FY23: -222.5M FY24: -466.6M FY25: -664.6M FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-750M -500M -250M 0 250M 500M 750M FY14: -7M FY15: -25.5M FY16: -23.2M FY17: -68.4M FY18: -165M FY19: 66.9M FY20: -348.9M FY21: 377.7M FY22: -650.2M FY23: -153.6M FY24: -366.3M FY25: -581.6M FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY14: -4.8M FY15: 59.4M FY16: -52.9M FY17: -70.1M FY18: -96.2M FY19: 56.7M FY20: -238.4M FY21: 539M FY22: -495.7M FY23: -260.4M FY24: -142.8M FY25: -345M FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY15: 58.3M FY16: -55.9M FY17: -77.9M FY18: -99M FY19: 50M FY20: -256.7M FY21: 457.3M FY22: -532.9M FY23: -269.8M FY24: -144.7M FY25: -345.9M FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 35M 70M 105M FY17: 40.1M FY18: 48M FY19: 56.9M FY20: 65.9M FY21: 80.4M FY22: 77.7M FY23: 79.2M FY24: 84.4M FY25: 89.9M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '15: -5.08 Q1 '16: -5.70 Q2 '16: -8.05 Q3 '16: -9.67 Q4 '16: -7.05 Q1 '17: -6.06 Q2 '17: -3.47 Q3 '17: -1.32 Q4 '17: -1.72 Q1 '18: -1.80 Q2 '18: -2.06 Q3 '18: -2.51 Q4 '18: -3.43 Q1 '19: -3.74 Q2 '19: -3.93 Q3 '19: -0.46 Q4 '19: 0.97 Q1 '20: 0.75 Q2 '20: 0.46 Q3 '20: -3.26 Q4 '20: -5.27 Q1 '21: -5.63 Q2 '21: 5.11 Q3 '21: 4.76 Q4 '21: 4.70 Q1 '22: 3.89 Q2 '22: -7.95 Q3 '22: -8.52 Q4 '22: -8.36 Q1 '23: -6.71 Q2 '23: -5.29 Q3 '23: -4.46 Q4 '23: -1.94 Q1 '24: -2.70 Q2 '24: -3.21 Q3 '24: -2.81 Q4 '24: -4.35 Q1 '25: -4.50 Q2 '25: -5.41 Q3 '25: -5.57 Q4 '25: -6.50 Q1 '26: -6.20 Q2 '26: -4.74 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.